ThermoFisher

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Reuters - 2 days ago

US urges makers of infant RSV shots to meet winter demand

UPDATE 2-US urges makers of infant RSV shots to meet winter demand Adds details on Thermo Fisher in paragraph 7 Dec 7 (Reuters) - U.S. officials met with manufacturers of the infant and toddler RSV immunization Beyfortus this week seeking to boost access to the shot, the White House said in a statement on Thursday after senior Biden administration officials met with the companies last week .

Reuters - 3 days ago

US urges RSV vaccine makers to meet winter demand, White House says

US urges RSV vaccine makers to meet winter demand, White House says WASHINGTON, Dec 7 (Reuters) - U.S. officials met again with RSV vaccine manufacturers this week amid ongoing efforts to boost access to the shots, the White House said in a statement on Thursday after senior Biden administration officials met with the companies last week . The officials on Tuesday met with representatives of Sanofi SA SASY.PA , AstraZeneca AZN.L and Thermo Fisher TMO.N "and urged them to work expeditiously to me

Reuters - 4 days ago

Thermo Fisher Scientific Says Establishes 2030 Renewable Electricity Goal And Solar Power Purchase Agreement With Ib Vogt

BRIEF-Thermo Fisher Scientific Says Establishes 2030 Renewable Electricity Goal And Solar Power Purchase Agreement With Ib Vogt Dec 6 (Reuters) - Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC ESTABLISHES 2030 RENEWABLE ELECTRICITY GOAL AND SOLAR POWER PURCHASE AGREEMENT WITH IB VOGT PROJECT IS EXPECTED TO BE OPERATIONAL IN JANUARY 2

Reuters - 1 week ago

Thermo Fisher Scientific Extends The Expiration Of Tender Offer For All Outstanding Common Shares And Adss Of Olink

BRIEF-Thermo Fisher Scientific Extends The Expiration Of Tender Offer For All Outstanding Common Shares And Adss Of Olink Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC EXTENDS THE EXPIRATION OF TENDER OFFER FOR ALL OUTSTANDING COMMON SHARES AND ADSS OF OLINK THERMO FISHER SCIENTIFIC INC - OFFER NOW SCHEDULED TO EXPIRE AT 5:00 P.M.,

Reuters - 2 weeks ago

Thermo Fisher Scientific Prices Offering Of Denominated Senior Notes

BRIEF-Thermo Fisher Scientific Prices Offering Of USD-Denominated Senior Notes Nov 28 (Reuters) - Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC PRICES OFFERING OF USD-DENOMINATED SENIOR NOTES PRICED AN OFFERING OF $2.5 BILLION AGGREGATE PRINCIPAL AMOUNT PRICING OF $1.0 BILLION PRINCIPAL AMOUNT OF ITS 5.000% SENIOR NOTES DUE 2026 AT

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.